Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
On November 12, 2026, Health
In Tech, Inc., a Nevada corporation (the “Company”), hosted a conference call to discuss its financial and operating results
for the quarter ended September 30, 2026. A transcript of the conference call is furnished as Exhibit 99.1 to this Current Report on Form
8-K. As previously disclosed, a replay of the entire conference call is available for on-demand listening through approximately 90 days
after the date hereof via the Investor Relations page of the Company’s website at https://healthintech.investorroom.com.
The information set forth
in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 are deemed to be “furnished” and shall not
be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on
Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities
Act of 1933, as amended, regardless of any general incorporation language in such filing.
Certain statements in this
Current Report on Form 8-K or the accompanying exhibits are forward-looking statements for purposes of the safe harbor provisions under
the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health
In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive
position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms
such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,”
“expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,”
“believe,” “continue,” “predict,” “project,” “potential,” “goal,”
“objective” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events
or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may
cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results,
levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance
on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases,
beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements.
Some of the risks and uncertainties, although not all risks and uncertainties, that could cause the Company’s actual results to
differ materially from those presented in its forward-looking statements are set forth in the “Risk Factors” section in the
Company’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and all of its other filings with the U.S. Securities
and Exchange Commission, as such risks, uncertainties and other important factors may be updated from time to time in the Company’s
subsequent reports. Any forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject
to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy
and liquidity. Health In Tech undertakes no obligation to update any forward-looking statements, except as required by law.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTH IN TECH, INC.
Exhibit 99.1
HIT Q3 2026 Earnings Conference Call
November 12, 2026
5:00 PM ET
Operator | Opening
Good afternoon, ladies and gentlemen, and welcome to Health In Tech’s
Third Quarter 2026 Earnings Conference Call. All participants are currently in listen-only mode. After the prepared remarks, we will
open the call for questions. As a reminder, today’s conference call is being recorded. If you have any objections, you may disconnect
at this time.
I will now turn the call over to Lori Babcock, Chief of Staff. Lori,
please go ahead.
Lori Babcock | Introduction and safe harbor
Thank you, operator, and good afternoon, everyone. Welcome to Health
In Tech’s third quarter 2026 earnings call.
Joining us today are Tim Johnson, our Founder and Executive Chairman;
Sanjay Shrestha, our Chief Executive Officer; and Julia Qian, our Chief Financial Officer.
The details of our results are in today’s earnings release and
our related Form 10-Q to be filed with the SEC. Both will be available on our Investor Relations website at healthintech.investorroom.com,
where a replay of this call will also be posted.
Before we continue, please note that today’s discussion includes
forward-looking statements under the safe harbor provisions of the federal securities laws. These statements reflect our current expectations
and involve risks and uncertainties that could cause actual results to differ materially. Please refer to our earnings release and SEC
filings for the applicable risk factors. We undertake no obligation to update these statements except as required by law.
We may also discuss non-GAAP measures, including adjusted EBITDA.
The relevant definitions and reconciliations to GAAP measures will be provided in our earnings release.
With that, I’ll turn the call over to Tim.

Tim Johnson | Executive Chair – Leadership Transition
Before we discuss our business performance and outlook, I would like
to take a moment to highlight an important leadership transition at Health In Tech and formally introduce Sanjay Shrestha as our new
Chief Executive Officer.
Since founding Health In Tech, my vision has been to transform the
health insurance industry through technology, innovation, and vertical integration. Over the years, we have built a differentiated technology
platform designed to simplify complex processes, improve efficiency, and create greater transparency across the health insurance marketplace.
As we look toward the next chapter of our growth, I believe the Company
has reached an important stage in its evolution. While innovation and technology development will always remain central to our business,
our next phase requires an even greater emphasis on commercial execution, operational scalability, business expansion, and the ability
to capitalize on strategic growth opportunities.
That is the rationale behind our leadership transition.
By separating the roles of Executive Chairman and Chief Executive
Officer, we are creating a leadership structure that allows us to dedicate greater focus and resources to two equally important priorities:
continuing to innovate and build for the future, while accelerating execution and scaling the business we have established.
In my role as Executive Chairman, I will remain actively involved
in shaping the Company’s long-term strategy, advancing technology innovation, and guiding product development. I will also continue
to leverage my industry experience and relationships to identify emerging opportunities and help position Health In Tech for long-term
success.
Sanjay, as CEO, will lead our day-to-day operations and be responsible
for driving commercial execution, strengthening our organizational capabilities, scaling our existing business, and improving overall
operating performance.

Importantly, Sanjay will also lead our efforts to identify and evaluate
potential strategic acquisitions, partnerships, and other business expansion opportunities. We believe that combining organic growth
with disciplined strategic acquisitions could provide additional avenues to expand our capabilities, strengthen our market position,
and create meaningful long-term value for shareholders.
Sanjay brings extensive experience
in public-company leadership, capital markets, corporate strategy, and business development. Having previously served on our Board and
worked closely with our leadership team, he already has a strong understanding of our business, our technology, and the opportunities
ahead.
I believe his experience and capabilities
complement my own, and that together, we can strengthen Health In Tech’s ability to translate our innovation and strategic vision
into sustainable business growth.
I also want to emphasize that
my transition to Executive Chairman is not a step away from Health In Tech. My commitment to the Company, our employees, our partners,
and our shareholders remains as strong as ever. This transition allows me to focus more of my time and energy on long-term strategy,
innovation, and the next generation of products and opportunities, while Sanjay provides dedicated leadership to execute and scale our
business.
Ultimately, this is about building
a stronger Health In Tech — one with the leadership capacity to innovate, execute, expand, and pursue opportunities that enhance
long-term shareholder value.
I am excited about this next chapter
and confident in the leadership team we are building.
With that, it is my pleasure to
welcome Sanjay Shrestha as Chief Executive Officer of Health In Tech.
Sanjay, I will turn the call over
to you.
Sanjay Shrestha | CEO — Accountability, commercial priorities
Thank you, Tim, and good afternoon, everyone.
It is a pleasure to join you today for my first earnings call as Chief
Executive Officer of Health In Tech.
I would like to use this opportunity to share my perspective on the
business, the opportunities ahead of us, and, importantly, the priorities I believe will be critical to translating those opportunities
into sustainable growth and long-term shareholder value.
Having served on Health In Tech’s Board and subsequently as
a strategic advisor, I have had the opportunity to develop a strong understanding of the Company’s technology, business model,
industry relationships, and long-term potential.
Stepping into the CEO role, however, provides an even closer perspective
on our day-to-day operations, commercial execution, and opportunities to strengthen our performance.

And one thing has become very clear to me: **We believe Health In
Tech has built a strong foundation. Our key focus and strategic priority is to translate that foundation into scalable commercial
growth and stronger financial performance.
2026: A Year of Investment and Building for the Future
Let me begin by putting 2026 into perspective.
This has been an important year of investment and capability building
for Health In Tech.
We have invested in expanding our sales and distribution network,
strengthening relationships with brokers, carriers, managing general underwriters (“MGUs”), and strategic partners, and continuing
to develop the underlying technology that supports our marketplace.
At the same time, we have advanced several significant initiatives,
including HitRix, HITChain, and our Three-Year Rate Stabilization Program.
Each of these initiatives addresses substantial market opportunities
in areas of the healthcare insurance ecosystem where we believe there has been relatively limited technological innovation.
Our objective has not been solely to maximize near-term revenue. We
have been building the technology, distribution relationships, financial infrastructure, and product capabilities that we believe can
support a much larger and more diversified business over time.
That said, we recognize that certain initiatives have taken longer
than originally anticipated.
Product commercialization has required more time. Bringing additional
carrier capacity online has taken longer than expected. And coordinating the multiple participants required to launch some of our newer
products has introduced additional complexity.
As a result, the financial contribution from several important initiatives
has been pushed beyond our original expectations.
I want to be clear: we are not satisfied with our current revenue
performance.
Investment is necessary, but investment alone does not create value
for all stakeholders. Ultimately, those investments need to be translated into customer adoption, transaction volume, revenue growth,
and improved financial performance.
That is the standard by which we intend to measure our progress going
forward.
Throughout my career, I have worked with businesses where the market
opportunity was substantial, but realizing that opportunity required aligning commercial execution, operational discipline, organizational
capabilities, and capital allocation.
I have substantial operational experience scaling new product from
incubation to meaningful commercial scale, building large scale process plants, and renewable assets on global basis.

I share that experience not to suggest that Health In Tech will follow
the same trajectory or timetable, but because I have seen firsthand what becomes possible when a compelling business opportunity is supported
by the right strategy, people, execution capabilities, and disciplined capital allocation.
My first priority is to be laser focused on re-accelerating our
core business to improve outcomes for all stakeholders, including our carrier partners, MGUs, brokers, third party administrators (“TPAs”)
and most importantly our clients who are looking for attractive/economical health coverage.
I will discuss in more detail our newer initiatives that we believe
will offer substantial future opportunities. I believe it is important to reiterate that we have an existing core business with meaningful
commercial activity and a growing network of distribution partners.
We are focused on execution and reaccelerating this business as we
look into 2027.
Our existing platform and MGU-related solutions support the self-funded
medical stop-loss market, including employers across small- and large-group segments.
These offerings provide an established commercial foundation upon
which we believe we can expand.
As of October 30, 2026, our platform had approximately $150 million
in potential annualized revenue associated with quoting activity for policies with anticipated effective dates in November 2026, December
2026, and January 2027.
Approximately 70% of that pipeline was associated with January 1,
2027, anticipated policy effective dates, and we expect quoting activity for that period to continue developing.
I want to emphasize that this pipeline represents potential business
opportunities, not contracted or recognized revenue. Actual conversion will depend on underwriting, pricing, broker and employer decisions,
carrier capacity, and successful policy placement.
For me, this creates a clear and immediate execution priority.
We need to focus on converting qualified opportunities into bound
policies and ultimately recognized revenue.
That means working more proactively with brokers, distribution partners,
carriers, and MGUs to identify and resolve obstacles that may delay or prevent conversion.
We are placing greater emphasis on active pipeline management, stronger
follow-through, improved coordination, and accountability throughout the quoting and placement process.
Rather than measuring success simply by the volume of opportunities
entering the platform, we need to focus on how effectively those opportunities progress through the commercial process.
This includes tracking conversion rates, identifying bottlenecks,
strengthening partner engagement, and improving the overall efficiency of underwriting and policy placement.

We also see opportunities to better integrate the products and capabilities
within our broader ecosystem.
Our existing eDIYBS and SMR platforms, MGU-related solutions, HitRix,
and Three-Year Rate Stabilization Program address complementary needs across the self-funded insurance marketplace.
Together, they create opportunities to serve a broader range of employers,
strengthen partner relationships, and potentially capture additional value throughout the insurance distribution and underwriting process.
Our goal is to make it easier for our partners to conduct business
through Health In Tech and to build a marketplace that becomes increasingly valuable as participation and transaction activity grow.
This is where I believe disciplined commercial execution can have
a meaningful impact on our near-term performance.
Priority Two: Commercializing Our New Growth Initiatives
As we remain focused on driving our base business, we are equally
excited about moving our newer products and strategic initiatives from development into commercialization.
We believe three of these strategic initiatives have the potential
to meaningfully expand our addressable market and diversify and complement our future revenue opportunities: our Three-Year Rate Stabilization
Program, HitRix, and HITChain.
Let me briefly walk through each of them, their commercial potential,
and where we are in their development.
**Three-Year Rate Stabilization Program**
I want to spend a little more time on our Three-Year Rate Stabilization
Program because it represents a particularly compelling opportunity and involves a sophisticated structure that requires careful coordination
among multiple participants.
Traditionally, employers face annual uncertainty in their healthcare
insurance costs. For self-funded employers, this can create significant challenges in budgeting, financial planning, and managing healthcare
expenditures.
Our Three-Year Rate Stabilization Program is designed to address that
challenge through an innovative structure connecting employers, insurance carriers, capital markets participants, financial institutions,
trustees, and distribution partners.
The objective is straightforward: to provide employers with greater
predictability in their healthcare insurance costs over a three-year period.
For employers, the program is designed to deliver greater budget certainty
and improved visibility into healthcare expenses.

For participating insurance carriers, it offers the opportunity to
establish longer-term customer relationships and evaluate insurance exposure over a three-year horizon, subject to defined underwriting
parameters and risk-management safeguards.
For investors, the structure contemplates notes supported by credit
enhancement from a financial institution, with scheduled principal and interest payments governed by the transaction documents.
Health In Tech’s role is to serve as the technology and administrative
platform connecting these participants. We coordinate program administration, documentation, communications, collections, and integration
with the financial and insurance underwriting processes.
Our distribution partners manage employer relationships and coordinate
the insurance underwriting process.
As you can appreciate, successfully launching a program of this complexity
requires precise coordination across insurance underwriting, financial structuring, capital markets execution, regulatory requirements,
and technology infrastructure.
That complexity also illustrates the importance of disciplined implementation.
We have already secured our initial client under a medical stop-loss
agreement and are working toward the capital markets launch.
The program financing associated with this initial client remains subject
to final structuring and market conditions.
Beyond this initial transaction, we believe there is substantial market
interest and opportunity in the program. Importantly, any program financing amounts and pipeline values should not be confused with revenue
to Health In Tech.
Our immediate objective is our goal of completing the first end-to-end
program launch by the end of 2026.
A successful initial transaction would establish an important operational
and commercial foundation for broader deployment.
Looking into 2027, our focus will be on converting qualified pipeline
opportunities into contracted programs and expanding adoption through our distribution partners.

While the timing and ultimate conversion of these opportunities will
depend on underwriting, contractual, financing, and execution requirements, we believe this program has the potential to become a meaningful
new business line for Health In Tech over the next several years.
**HitRix — AI-Powered Large-Group Insurance Marketplace**
Our second major initiative is HitRix, an AI-powered platform designed
to modernize the quoting, underwriting submission, and placement process for larger employer health plans.
Today, large-group insurance placements remain highly fragmented and
manually intensive.
Brokers routinely manage substantial volumes of employee census data,
historical claims information, plan documents, and supporting underwriting materials across multiple formats and systems.
They must prepare submissions for different insurance carriers and
MGUs, track responses, compare proposals, and coordinate the placement process.
This creates considerable administrative work, inefficiencies, and
delays.
HitRix is designed to transform that workflow.
Using AI-powered document intelligence, the platform can ingest, extract,
normalize, and structure information from files brokers already receive, reducing the need for manual data entry and repetitive reformatting.
It then enables brokers to manage submissions across multiple carriers
and MGUs, track market activity, organize proposals, and compare alternatives within a unified environment.
The objective is to allow brokers to spend less time managing documents
and spreadsheets and more time advising their clients and growing their businesses.
What makes HitRix particularly compelling is its integration with
Health In Tech’s broader underwriting and marketplace infrastructure.
Rather than functioning simply as a document management or submission
tool, HitRix is designed to connect data processing, market access, analytics, underwriting workflows, and transaction execution.
We believe this positions us to address a large, existing market where
billions of dollars in annual premiums are supported by workflows that remain heavily dependent on manual processes.
Equally important, we are not bringing this product to market without
an established distribution foundation.

As of September 30, 2026, our ecosystem included 984 broker, third-party
administrator, and agency partners, representing 15.9% year-over-year growth.
These are relationships we have invested years in building.
As we introduce HitRix, we have an opportunity to offer additional
capabilities to partners who already understand our marketplace and business model.
We also see an opportunity to deepen our relationships with participating
carriers and MGUs, expand market access, and support more efficient policy placement.
Over time, as transaction activity increases, HitRix could also generate
a growing base of structured underwriting and placement data, supporting future analytics, automation, and AI-enabled capabilities.
Our current objective is to launch the minimum viable product in the
first quarter of 2027 and progressively expand its capabilities and commercial adoption throughout the year.
**HITChain — Transforming Healthcare Claims Administration**
Our third initiative is HITChain.
HITChain addresses another significant source of inefficiency in the
healthcare system: the administrative complexity associated with claims processing, reconciliation, and provider payments.
The U.S. healthcare system incurs substantial administrative costs,
with industry estimates placing the broader healthcare administration opportunity in the hundreds of billions of dollars annually.
We believe blockchain-enabled verification, combined with AI-powered
automation, has the potential to significantly improve the speed, transparency, and efficiency of certain claims administration processes.
HITChain is designed to connect healthcare providers, third-party
administrators, employers, and other authorized participants through secure, verifiable data and transaction workflows.
For hospitals, clinics, and other healthcare providers, the opportunity
is to shorten payment cycles, reduce reconciliation requirements, and improve working capital efficiency.
Our longer-term vision is to reduce certain payment processes that
traditionally take weeks to a much shorter settlement period, potentially approaching next-day settlement where the necessary conditions
are met.
For TPAs, the platform is intended to automate aspects of claims administration,
improve processing efficiency, and reduce manual intervention.
For employers, HITChain could provide greater transparency into claims
activity, more timely access to information, and opportunities to benefit from faster payment arrangements and improved cost management.

We believe the combination of AI-driven processing and verifiable
transaction infrastructure offers a meaningful opportunity to modernize parts of the healthcare payment ecosystem.
Our objective is to launch an initial minimum viable product during
the second half of 2027.
As with our other new initiatives, our focus is on validating the
technology, establishing the necessary ecosystem relationships, and creating a clear path toward commercialization.
Taken together, these three initiatives illustrate the breadth of
opportunity we see ahead of Health In Tech.
But the most important point is this: “we are moving from a
period primarily focused on building new capabilities toward one increasingly focused on bringing those capabilities to market and generating
measurable commercial results.”
My third and somewhat of an obvious priority is to strengthening
Operational Discipline and Financial Performance
Our third priority is to strengthen how we operate the business and
allocate capital.
We have invested significantly in technology, product development,
sales capabilities, and infrastructure.
As a result, our operating cost structure reflects the investments
we have made to support future growth.
Going forward, we need to be increasingly disciplined about where
we deploy resources and how we measure the returns on those investments.
The questions I will be asking are straightforward.
Where are we generating the greatest commercial returns?
Which initiatives are positioned to contribute most meaningfully to
revenue and profitability?
Where do we need additional capabilities to accelerate execution?
And where can we improve efficiency, simplify processes, or redeploy
capital to higher-value opportunities?
This is not about cutting our way to growth.
It is about building an organization where investment decisions, operating
priorities, and financial outcomes are closely aligned.
We will also be focused on strengthening our organizational capabilities,
improving accountability, and establishing clearer performance metrics across the business.

On the financial side, working capital management, cash flow, and
capital allocation will remain important priorities.
We have seen sequential improvements in operating cash usage from
the first quarter to the second quarter of 2026, which is encouraging. However, we recognize that continued improvement will require
disciplined execution and careful management of our financial resources.
As we commercialize our new products and expand our existing business,
we will evaluate the appropriate level of investment, the timing of capital deployment, and the potential returns associated with each
opportunity.
In addition to organic growth, we will evaluate strategic acquisitions,
investments, and partnerships that could complement our technology platform, strengthen our market position, expand our capabilities,
and/or accelerate our growth strategy.
We will be disciplined in evaluating those opportunities, with a focus
on strategic fit, execution risks, capital requirements, and long-term shareholder value creation.
Our objective is not growth for its own sake. It is to build a business
capable of generating sustainable growth, improving profitability, and delivering attractive returns on invested capital.
As I look ahead, I am encouraged by the opportunities in front of
us, but I am equally focused on the work required to realize them.
Health In Tech has established an innovative technology foundation,
developed meaningful industry relationships, and invested in several initiatives that we believe address significant market opportunities.
The next phase is about execution.
In the near term, that means improving conversion across our existing
business, continuing to bring our Three-Year Rate Stabilization Program to market, and maintaining disciplined operational and financial
management.
As we move into 2027, our priorities will include scaling HitRix,
advancing HITChain, expanding our distribution capabilities, and evaluating strategic growth opportunities that can further strengthen
the business while simultaneously remaining laser focused on reaccelerating our existing base of business.
We will measure our progress not simply by the size of the markets
we address or the opportunities in our pipeline, but by our ability to convert those opportunities into revenue, operating performance,
cash generation, and long-term shareholder value.
I am excited to work closely with Tim, our Board, and the entire Health
In Tech team as we move into this next chapter.

So how should investors think about the remainder of 2026 and 2027?
We updated our full-year 2026 revenue outlook to approximately $30
million.
For the balance of 2026, our focus is really on execution ahead of
the renewal and placement cycle. We want to get brokers using the products, expand participation from underwriting partners, work through
the opportunities already in front of us and be better positioned as those policy effective dates come around.
As we move into 2027, we believe there is an opportunity for these
initiatives to make a more meaningful contribution. That’s our current view. But I also want to put an important qualifier around
it: I’ve been in the CEO role for only a short time, and this is still an ongoing review. Some of the priorities, sequencing and
capital decisions may change as we learn more. I’m not presenting a finalized 2027 plan today.
What I would like to do is come back to investors with a more detailed
discussion of our operating priorities and how we intend to measure progress when we report our full-year 2026 results, subject, of course,
to completing that review.
Look, I think there is a lot to work with here. We have technology
that’s been built, products that address real problems, and relationships across the self-funded market. But we’ve got to
turn those assets into more consistent commercial results, and we’ve got to do it with the right financial discipline.
That’s what I’m focused on. Tim will continue to spend
his time on innovation and the longer-term direction of the platform. My job is to connect that vision to the operating decisions that
can move this business forward. I look forward to working with the team and keeping you updated as that work progresses.
With that, Julia, let me turn it over to you for the financial review.
Julia Qian | CFO — Q3 financial results and outlook
Thank you, Sanjay. Good afternoon, everyone. As Sanjay noted, we believe
our reported results this quarter do not yet reflect the opportunity we are building toward. I want to help bridge that gap, by starting
with the forward-looking metrics that show where the commercial activity on our platform actually stands today, and then walking through
what sits underneath the reported numbers.
Let me begin with our forward revenue visibility.
Contracted revenue, which represents revenue that is already contractually
committed under active policies but that has not yet been recognized under GAAP, totaled $32.7 million for the first nine months of 2026.
Of that amount, $24.4 million has already been recognized as GAAP revenue through September 30, 2026, before the enrollment adjustment
and refund liability, and with $6.1 million scheduled to be recognized in the fourth quarter and $2.2 million flowing into 2027. Put another
way, before we count a single new sale in the fourth quarter, we have already secured $30.5 million of 2026 revenue, with the remaining
$2.2 million providing a visible starting point for 2027.

Beyond what is already contracted, our pipeline revenue, which represents
policies currently in quoting or binding stage plus policies that have been contracted since quarter end, stood at $156.4 million as of
October 30, 2026.- which are for the 3 months only Nov, Dec and January 2027 Of that pipeline, $2.6 million is already contracted in October
and the remaining $153.8 million carries an expected conversion range of 3% to 7% meaning would generate $9.2m to $10.7m revenue just
for these three months policies. And our platform placed plan value, or PPPV, which measures the aggregate contractual value of plans
on our platform including premium, claim funding and administrative fees, stood at $91.8 million as of September 30, 2026.
I want to put these numbers in context. Our sales pipeline grew meaningful
driven by full completion of onboarding new carrier and entering to the peak season of our sales cycle. – for Dec and Jan effective
date policies.
Now, the next step is laser-focused to drive conversion rate of pipeline
revenue to contractual revenue. Our distribution model relies on close collaboration between our internal sales team and our network of
broker partners. As we introduce new products and expand our marketplace capabilities, making sure our brokers fully understand these
solutions and how to bring them to market becomes increasingly important.
Following the recent launch of HitRix, we’re placing greater
emphasis on internal sales training and broker education to strengthen that collaboration. Our goal is to equip our team to better support
brokers throughout the submission and placement process, helping move more opportunities toward completed placements.
As we enter the year-end renewal season, we believe these efforts,
together with broader carrier participation, can help improve the conversion of our existing pipeline into contracted business and ultimately
recognized revenue.
Our distribution footprint also continued to expand. We ended the
quarter with 984 distribution partners, compared with 849 a year ago, representing an approximately 15.9% year-over-year increase, which
tells you the broker, TPA and agency network that brings business onto our platform is continuing to grow even through this transition
period.
Now turning to reported GAAP revenue. Total revenue for the
third quarter was $6.6 million compared with $8.5 million a year ago, and for the first nine months of 2026, revenue was $23.4 million,
compared with $25.8 million last year.
Our SMR fee revenue, which is earned on a per enrolled employee per
month basis across our platform, was essentially unchanged year over year on a nine-month basis, at $20.04 million compared with $19.99
million in the prior-year period. Our underwriting modeling revenue, which our ICE subsidiary earns as a specified percentage of carrier
premium, declined more sharply to $3.37 million for the first nine months of 2026 compared with $5.83 million a year ago. In other words,
our largest revenue line, the enrollment-based SMR fee, held essentially steady year over year even through the carrier transition, and
the compression in reported revenue was concentrated in the premium-based ICE line rather than reflecting broad-based weakness across
the business. So the pressure on reported revenue reflects timing of recognition from the carrier transition that in our view is now
substantially behind us.

Gross margin for the third quarter was 46.5% compared with
60.6% a year ago, and for the first nine months of 2026 was 49.1% compared with 65.1% in the prior year. As mentioned last quarter, beginning
in January 2026, we introduced pre-designed self-funded health plans that combine our platform capabilities with additional services,
including plan administration provided by TPAs and other vendors. Under this expanded service model, the related TPA and vendor fees
are included in our cost of revenues. As a result, we’re now delivering a more comprehensive solution to our customers, but we’re
also incurring additional direct service costs, which has contributed to the year-over-year decline in gross margin, even though the
underlying economics of the business have not changed. We see this as a trade-off as we expand our service offering and make it easier
for brokers and employers to access a more integrated solution. We believe our gross margin should maintain in the range of 45%-50% in
the coming quarters.
Moving to operating expenses. Total operating expenses for the third quarter were $11.5 million compared
with $4.7 million a year ago. The $6.8 million year-over-year increase was mainly driven by a provision charge of $5.3 million and higher
sales and marketing spend of $1 million, with Tech development expense up $0.7 million, partially offset by $0.3 million in general and
administrative savings.
Starting with sales and marketing. Sales and marketing expenses were
$2.1 million for the quarter compared with $1.0 million a year ago. The increase is almost entirely variable in nature. The largest driver
is tied to our expanding our distribution channels through third-party agents, which are variable and based on policies sold and fees
collected, The fixed component of our sales and marketing spend has remained disciplined, consistent with our capital-light distribution
partner-driven model.
General and administrative expenses were $3.1 million for the quarter
compared with $3.5 million a year ago, and $10.1 million for the first nine months of 2026 compared with $10.5 million in the prior-year
period. For both the quarter and the nine-month period, G&A actually came in slightly below the prior year, which reflects disciplined
cost management across our corporate functions. Within the mix, our operations division expenses decreased year over year as a result
of workforce optimization initiatives we have been executing, partially offset by higher administrative division costs primarily driven
by stock-based compensation. Taken together, this demonstrates our commitment to managing our cost base while continuing to invest where
it matters for the long term.
Provision for credit losses was $5.3 million for the quarter and $6.1
million for the first nine months of 2026, compared to essentially nil in the prior-year periods. This represented the single biggest
driver of the year-over-year change in operating expenses. The quarter’s provision reflects management’s updated assessment
of collectability and consists of approximately $2.4 million related to deferred administrative surplus receivables associated with a
specific legacy arrangement on which we took a full allowance, $1.9 million of bad debt expense related to accounts receivable connected
to the carrier transition reconciliations still in progress and $0.9 million related to a loan receivable. Given our internal decision
to focus on the US market first and limit overseas expansion for now, we chose to write off the advancement of marketing expense as a
form of loan and collect, which we viewed as the right display of discipline heading into a leadership transition and a fresh strategic
plan.

Research and development expenses were $0.9 million compared with
$0.2 million a year ago. This increase is a composition shift rather than a step-up in overall technology investment. If you look at
our total technology spend, meaning expensed R&D plus capitalized software development together, the total is broadly consistent
year over year. What changed is where it sits on the financial statements. Our development activities during 2026 have been weighted
more toward gathering business requirements, identifying features, and evaluating alternatives as we scope our next-generation platform
and AI-powered capabilities. Under GAAP, these early-stage planning and evaluation activities do not meet the criteria for capitalization
and instead flow through the income statement as R&D expense. So the increase on the R&D line reflects where we are in the development
cycle, not an increase in total technology spend.
That brings me to profitability. Adjusted EBITDA for the quarter
was negative $3.9 million compared with positive $1.0 million a year ago, and for the first nine months of 2026 was negative $6.6 million
compared with positive $3.8 million in the prior-year period.
Net loss for the quarter was $7.1 million, which included the $5.3
million one-time credit loss provision I just walked through, or $(0.11) per basic and diluted share, compared with net income of $0.5
million, or $0.01 per diluted share, in the prior-year quarter. For the first nine months, net loss was $11.2 million, which included
$6.1 million of one-time credit loss provision, or $(0.18) per basic and diluted share, compared with net income of $1.6 million, or
$0.03 per diluted share, in the prior-year period. Excluding the one-time provisions, the remaining year-over-year decline reflects lower
revenue due to the timing of policy effective dates during the carrier transition, the plan administrative service costs tied to our
new self-funded plan administration service launched in January, our continued investment in sales, marketing and technology to support
long-term growth, and financing-related charges tied to the capital raises completed this quarter.
Turning to cashflow. Our operating cash flow has improved every
single quarter this year. We had negative $3.3 million of operating cash in the first quarter, negative $2.9 million in the second quarter,
and negative $1.0 million in the third quarter. We are improving operational cashflow burn quarter by quarter, representing an approximately
68% reduction from the first quarter to the third quarter. The sequential improvement in the third quarter was driven by actual collection
of accounts receivable. In fact, accounts payable paid down during the third quarter, so this is a genuine working-capital-driven improvement,
not a cash preservation story. For the first nine months of 2026 as a whole, operating cash burn was $7.3 million. We expect further
improvement in operational cashflow as we commercialize new services and products in 2027.
We invested $1.8 million in software development during the first
nine months of 2026, reflecting our continued platform investment.
Turning to the balance sheet. We ended the quarter with $10.1 million in cash and cash equivalents,
compared with $7.7 million at the end of 2025. after absorbing $7.3 million of operating cash use and $1.8 million of software investment
through the first nine months of 2026, our cash position is approximately $2.5 million higher today than it was entering the year.

The headline message is that we built the capital base we needed, and
we are entering 2027 from a stronger balance sheet position than we entered 2026. with multiple new products that completed major developments
and will be commercialized in 2027, we are confident that 2027 would be a very different year.
To close. This was a transitional quarter, and the reported numbers
reflect three things happening at the same time: the carrier timing dynamic we described last quarter, a business mix shift that compresses
gross margin optically without changing the underlying economics, and balance sheet actions we chose to take . Our distribution network
expanded by approximately 15.9%, our operating cash use improved by approximately 68% from the first quarter to the third quarter of this
year, our cash balance ended the quarter higher than it was at the start of the year, and we built balance sheet capacity to support our
continued execution. As Sanjay mentioned, we are completing a comprehensive review of 2027 under his leadership, and we expect to come
back to the market at next quarter call to provide more detailed view of what 2027 looks like for Health In Tech.
With that, I will turn the call back to Sanjay.
Sanjay Shrestha | Closing and Q&A handoff
Thank you, Julia.
As we close our prepared remarks, I want to emphasize that we are
not satisfied with weaker revenue and higher expenses. We believe in the opportunity, but the responsibility to turn that opportunity
into results is ours.
We know the market will measure us by the progress we deliver in the
quarters ahead. We welcome that scrutiny, and we look forward to updating you with results.
With that, I’ll now turn it back to Operator to start Q&A.
Operator| Question-and-Answer Session
Thank you. Seeing no more questions in the queue, let me turn the
call back to Lori Babcock for closing statement.
Lori Babcock | Closing Statement
Thank you all again. This concludes the call. You may now disconnect.